Cancer Immunotherapy to Take Center Stage at ASCO

In early April 2010, we published a 150-page industry report titled “Cancer Vaccine Therapies: Failures and Future Opportunities,” which included an overview of the cancer immunotherapy market, interviews with several key opinion leaders, profiles of nearly 40 companies, and a discussion of the scientific, clinical, and commercial considerations for the major industry participants.   An executive … Read moreCancer Immunotherapy to Take Center Stage at ASCO

Keryx: Another beneficiary of the ASCO-effect

In my prior article, I highlighted the “ASCO-effect,” which relates to the fact that biotechnology companies working in the field of cancer can experience double or triple-digit stock price increases from the end of April through the American Society of Clinical Oncology (ASCO) annual meeting. Beyond the names previously mentioned, investors also appear to be … Read moreKeryx: Another beneficiary of the ASCO-effect

Biotech Stocks and the ASCO-effect

Investors are hoping that the spark that could reignite investor enthusiasm for biotech stocks is taking place right now. Approximately 30,000 participants are gathering from May 29-June 2, 2009, in Orlando, Florida, for the year’s largest cancer conference. Attendees of the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) will exchange ideas … Read moreBiotech Stocks and the ASCO-effect